← Open Payments lookup

NPI 1437131257: Open Payments

NPI 1437131257. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,408 in 49 payments from 12 companies in 2025. Trend: 2023 $2,497 · 2024 $2,625 · 2025 $1,408

Food & beverage: $1,195Education: $213
CompanyPaymentsAmount
Teva Pharmaceuticals USA, Inc.21$599
Alkermes, Inc.4$189
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)2$145
Neurocrine BioSciences, Inc.4$94
Otsuka America Pharmaceutical, Inc.4$93
Vanda Pharmaceuticals Inc.4$78
E.R. Squibb & Sons, L.L.C.3$70
Axsome Therapeutics, Inc.2$45
ABBVIE INC.2$39
Takeda Pharmaceuticals U.S.A., Inc.1$24

Products named: AUSTEDO XR, UZEDY, CAPLYTA, ARISTADA, INGREZZA, HETLIOZ, COBENFY, Auvelity.